TargetBeta
FGF21
fibroblast growth factor 21 · Fibroblast growth factor family
4 programs in company-led studies act on FGF21, from 3 companies: 3 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| efimosfermin alfa | GlaxoSmithKline | – | phase 3 | 107 running | – | the company's pipeline |
| pegozafermin | 89bio | – | phase 3 | 83 running | – | a judged reading |
| efruxifermin | Novo Nordisk | – | phase 3 | 63 running | – | a judged reading |
| zalfermin | Novo Nordisk | – | phase 2 | 101 running | – | a judged reading |
Conditions their studies are in
- Non-alcoholic Fatty Liver Disease, 4 programs
- Obesity, 2 programs
- Diabetes Mellitus, Type 1, 1 program
- Diabetes Mellitus, Type 2, 1 program
- Fatty Liver, 1 program
- Hypertriglyceridemia, 1 program
- Liver Diseases, Alcoholic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 2, 2027pegozafermin · 89bio · phase 3 · NCT07835243
- Oct 13, 2027efimosfermin alfa · GlaxoSmithKline · phase 3 · NCT07358546
- Feb 2030efruxifermin · Novo Nordisk · phase 3 · NCT06528314
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.